Recombinant human interferon-α1b inhibits SARS-CoV-2 better than interferon-α2b in vitro

Virol Sin. 2022 Apr;37(2):295-298. doi: 10.1016/j.virs.2022.01.031. Epub 2022 Jan 25.

¹ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
² Shulan International Medical College, Zhejiang Shuren University, Hangzhou, 310015, China.
³ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China. Electronic address: flwnp2013@163.com.
⁴ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China. Electronic address: ljli@zju.edu.cn.
⁵ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China. Electronic address: yaohangping@zju.edu.cn.

Abstract

•
A comprehensive evaluation method for anti-SARS-CoV-2 drugs was established based on qPCR, TCID₅₀, and immunofluorescence.
•
A significant antiviral effect of rHuIFN-α1b was shown in Vero and Calu-3 cells.
•
rHuIFN-α1b has a good potential in the application of anti-COVID-19 therapy.